SOXC and miR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma

FERNANDA METREBIAN; HERNAN GARCIA RIVELLO; MIGUEL PAVLOVSKY; FUAD HUAMÁN GARAICOA; DANA KOHAN; ALEJANDRO ROISMAN; ASTRID PAVLOVSKY; MARINA NARBAITZ; IRMA SLAVUTSKY; ISOLDA FERNANDEZ; LUIS HERNANDEZ

Genes, Chromosomes and Cancer

John Wiley & Sons, Ltd.

Lugar: Chichester; Año: 2016 vol. 55 p. 531 - 540

Mantle cell lymphoma (MCL) is an heterogeneous B-cell lymphoid malignancy where most patients follow an aggressive clinical course whereas others associate with an indolent performance. SOX4, SOX11 and SOX12 constitute the SOXC family of transcription factors involved in embryonic neurogen¬esis and tissue remodeling. Among them, SOX11 has been found aberrantly expressed in most aggressive MCL patients, being considered a reliable biomarker in the pathology. Several studies have revealed that microRNAs (miRs) from the miR-17-92 cluster are among the most deregulated miRNAs in human cancers, still little is known about this cluster in MCL. In this study we screened the transcriptional profiles of 71 MCL patients for SOXC cluster and miR17, miR18a, miR19b and miR92a, from the miR-17-92 cluster. Gene expression analysis showed higher SOX11 and SOX12 levels compared to SOX4 (p≤0.0026). Moreover we found a negative correlation between the expression of SOX11 and SOX4 (p